Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 23, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan ("The Plan"). This resulted in an increase in the notional allocation of Ordinary Share ADRs on May 19, 2006, at a price of $56.44 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rule 3.1.4R(1)(a) regarding the transaction of Dr. R Greig.
Investor Verification Points
- Verify the specific impact of the US Retirement Savings Plan re-valuation on the notional holdings of Dr. R Greig.
- Confirm the transaction date of May 19, 2006, and the share price of $56.44 per ADR.
- Note that this filing does not contain updated financial statements or operational results for the company.